



## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbsilpa.com, Web: www.vbsilpa.com  
CIN: L85110KA1987PLC008739

**Date:** 04 February, 2025

To  
Corporate Relationship Department  
BSE Limited,  
1<sup>st</sup> Floor, Rotunda Building,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001.

To  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
MUMBAI – 400 051.

Dear Sir/Madam,

**Sub:** Analysts/Investors Call

**Ref:** Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q3 and 9M/FY2024-25 Conference Call, which is to be held on Tuesday, February 11, 2025 at 11:00 AM IST.

This is for your information.

Thanking you

**For Shilpa Medicare Limited,**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**

## Shilpa Medicare Limited

### Q3 and 9M FY25 Earnings Call

### February 11, 2025, at 11:00 AM

**Raichur, February 04, 2025:** Shilpa Medicare Ltd. (BSE- 530549, NSE- SHILPAMED, ISIN: INE790G01031), will announce its financial results for the quarter and nine months ended December 31, 2024, **on Monday, February 10, 2025**. Following the announcement, the management of the Company will host an **Earnings Call on Tuesday, February 11, 2025, at 11:00 AM IST**.

Details of Earnings Conference Call	
<b>Day/Date</b>	Tuesday, February 11, 2025
<b>Time (IST)</b>	11:00 AM
<b>Universal Access</b>	+91 22 6280 1107 +91 22 7115 8008
<i>The number listed above is universally accessible from all networks and all countries</i>	
International Toll-Free Numbers	
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448
DiamondPass™ Link	<a href="#">Click here</a> to join with DiamondPass™ (No Wait Time)
<b>Management Representation:</b>	
Mr. Keshav Bhutada, Executive Director (SPLL)	
Mr. Alpesh Dalal, Chief Financial Officer	
Mr. Monish Shah, Head-Strategy and IR	
<i>Participants are requested to dial-in 10 minutes before the scheduled time</i>	

#### **About Shilpa Medicare Limited (SML):**

Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio.

The company also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

#### **For further details, please get in touch with:**

##### **Shilpa Medicare Ltd**

Mr. Monish Shah/ Dilip Kankani  
B: +91-9819865421/+91 8532238704  
E: [monish.shah@vbsilpa.com](mailto:monish.shah@vbsilpa.com)  
[dilipkankani@vbsilpa.com](mailto:dilipkankani@vbsilpa.com)

##### **EY IR:**

Ms. Runjhun Jain / Ms. Sneha Salian  
M: +91-98207 20993/ +91-98194 30437  
E: [runjhun.jain1@in.ey.com](mailto:runjhun.jain1@in.ey.com) /  
[sneha2.salian@in.ey.com](mailto:sneha2.salian@in.ey.com)